Literature DB >> 18652856

PTD-modified ATTEMPTS system for enhanced asparaginase therapy: a proof-of-concept investigation.

Young Min Kwon1, Yong Tao Li, Jun F Liang, Yoon Jeong Park, Li-Chien Chang, Victor C Yang.   

Abstract

Macromolecular drugs such as proteins and gene products are presumably the most desirable therapeutic agents due to their unmatched substrate specificity and reaction efficiency. Yet, clinical use of these drugs has met with limited success, primarily due to the impermeable nature of the cell membrane that restricts cellular drug uptake to only small (<600 Da) and hydrophobic molecules. The recent discovery of the protein transduction domain (PTD) membrane-penetrating peptides, such as HIV-TAT, has finally offered the possibility of resolving this cell-membrane barrier for macromolecular drug delivery. Via covalent linkages, these PTD peptides have been shown to ferry the attached macromolecular species across membranes of all cell types, both in vitro and in vivo. Nevertheless, the lack of selectivity for PTD-mediated internalization restricts the application of this cell uptake method in clinical practice, due to concerns of inducing systemic toxicity caused by the carried drugs. Presented herein is a modified version of our previously established "ATTEMPTS" approach in delivery of macromolecular drugs, which integrates the cell-penetrating PTDs into a heparin/protamine-regulated delivery system. In vitro findings using asparaginase (ASNase) as a model macromolecular anti-tumor agent were able to validate the feasibility of this delivery system. The chemically constructed TAT-ASNase conjugates not only were able to translocate into the MOLT-4 cells and elicit the cytotoxic effects, but also this PTD-mediated intracellular drug uptake could be regulated (with on/off control) by the addition of heparin and protamine. This modified ATTEMPTS system therefore presents a new avenue of treatment of various types of cancers and other diseases with macromolecular drugs. In vitro characterization and a preliminary proof-of-concept animal investigation that demonstrates the feasibility of this PTD-mediated ASNase therapeutic system is subsequently described.

Entities:  

Mesh:

Substances:

Year:  2008        PMID: 18652856      PMCID: PMC2573869          DOI: 10.1016/j.jconrel.2008.06.017

Source DB:  PubMed          Journal:  J Control Release        ISSN: 0168-3659            Impact factor:   9.776


  30 in total

1.  Synthesis and characterization of positively charged tPA as a prodrug using heparin/protamine-based drug delivery system.

Authors:  J F Liang; Y T Li; M E Connell; V C Yang
Journal:  AAPS PharmSci       Date:  2000

2.  Substrate binding and intersubunit interactions in L-asparaginase.

Authors:  S Shifrin; C L Parrott; S W Luborsky
Journal:  J Biol Chem       Date:  1974-03-10       Impact factor: 5.157

3.  Reaction of fluorescein-isothiocyanate with proteins and amino acids. I. Covalent and non-covalent binding of fluorescein-isothiocyanate and fluorescein to proteins.

Authors:  H Maeda; N Ishida; H Kawauchi; K Tsujimura
Journal:  J Biochem       Date:  1969-05       Impact factor: 3.387

Review 4.  Delivery of molecular medicine to solid tumors: lessons from in vivo imaging of gene expression and function.

Authors:  R K Jain
Journal:  J Control Release       Date:  2001-07-06       Impact factor: 9.776

5.  Application of "ATTEMPTS" for drug delivery.

Authors:  Sarita S Naik; Jun-Feng Liang; Yoon Jeong Park; Won Kyu Lee; Victor C Yang
Journal:  J Control Release       Date:  2005-01-03       Impact factor: 9.776

6.  Anti-cancer protein transduction strategies: reconstitution of p27 tumor suppressor function.

Authors:  Eric L Snyder; Bryan R Meade; Steven F Dowdy
Journal:  J Control Release       Date:  2003-08-28       Impact factor: 9.776

7.  Subcellular trafficking of HPMA copolymer-Tat conjugates in human ovarian carcinoma cells.

Authors:  Aparna Nori; Keith D Jensen; Monica Tijerina; Pavla Kopecková; Jindrich Kopecek
Journal:  J Control Release       Date:  2003-08-28       Impact factor: 9.776

8.  Immunological responses to L-asparaginase.

Authors:  R G Peterson; R E Handschumacher; M S Mitchell
Journal:  J Clin Invest       Date:  1971-05       Impact factor: 14.808

9.  Intracellular tracking of protamine/antisense oligonucleotide nanoparticles and their inhibitory effect on HIV-1 transactivation.

Authors:  Norbert Dinauer; Dirk Lochmann; Ilhan Demirhan; Abdellatif Bouazzaoui; Andreas Zimmer; Angelika Chandra; Jörg Kreuter; Hagen von Briesen
Journal:  J Control Release       Date:  2004-05-18       Impact factor: 9.776

10.  Asparagine synthetase activity of mouse leukemias.

Authors:  B Horowitz; B K Madras; A Meister; L J Old; E A Boyes; E Stockert
Journal:  Science       Date:  1968-05-03       Impact factor: 47.728

View more
  14 in total

1.  Cell permeable cocaine esterases constructed by chemical conjugation and genetic recombination.

Authors:  Tien-Yi Lee; Yoon Shin Park; George A Garcia; Roger K Sunahara; James H Woods; Victor C Yang
Journal:  Mol Pharm       Date:  2012-03-28       Impact factor: 4.939

Review 2.  Harnessing the power of cell-penetrating peptides: activatable carriers for targeting systemic delivery of cancer therapeutics and imaging agents.

Authors:  Sarah R MacEwan; Ashutosh Chilkoti
Journal:  Wiley Interdiscip Rev Nanomed Nanobiotechnol       Date:  2012-09-13

Review 3.  Cell-penetrating peptides: achievements and challenges in application for cancer treatment.

Authors:  Meong Cheol Shin; Jian Zhang; Kyoung Ah Min; Kyuri Lee; Youngro Byun; Allan E David; Huining He; Victor C Yang
Journal:  J Biomed Mater Res A       Date:  2013-07-30       Impact factor: 4.396

Review 4.  Transduction of human recombinant proteins into mitochondria as a protein therapeutic approach for mitochondrial disorders.

Authors:  Lefkothea C Papadopoulou; Asterios S Tsiftsoglou
Journal:  Pharm Res       Date:  2011-08-27       Impact factor: 4.200

5.  PTD-Modified ATTEMPTS for Enhanced Toxin-based Cancer Therapy: An In Vivo Proof-of-Concept Study.

Authors:  Meong Cheol Shin; Jian Zhang; Kyoung Ah Min; Huining He; Allan E David; Yongzhuo Huang; Victor C Yang
Journal:  Pharm Res       Date:  2015-02-21       Impact factor: 4.200

Review 6.  Cell-penetrating peptides improve pharmacokinetics and pharmacodynamics of anticancer drugs.

Authors:  Izabela Rusiecka; Iwona Gągało; Ivan Kocić
Journal:  Tissue Barriers       Date:  2021-08-17

7.  L-Asparaginase encapsulated intact erythrocytes for treatment of acute lymphoblastic leukemia (ALL).

Authors:  Young Min Kwon; Hee Sun Chung; Cheol Moon; James Yockman; Yoon Jeong Park; Scott D Gitlin; Allan E David; Victor C Yang
Journal:  J Control Release       Date:  2009-07-03       Impact factor: 9.776

Review 8.  Curb challenges of the "Trojan Horse" approach: smart strategies in achieving effective yet safe cell-penetrating peptide-based drug delivery.

Authors:  Yongzhuo Huang; Yifan Jiang; Huiyuan Wang; Jianxin Wang; Meong Cheol Shin; Youngro Byun; Huining He; Yanqin Liang; Victor C Yang
Journal:  Adv Drug Deliv Rev       Date:  2013-01-28       Impact factor: 15.470

9.  Recombinant TAT-gelonin fusion toxin: synthesis and characterization of heparin/protamine-regulated cell transduction.

Authors:  Meong Cheol Shin; Jingwen Zhao; Jian Zhang; Yongzhuo Huang; Huining He; Mei Wang; Kyoung Ah Min; Victor C Yang
Journal:  J Biomed Mater Res A       Date:  2014-04-23       Impact factor: 4.396

10.  Chemically and biologically synthesized CPP-modified gelonin for enhanced anti-tumor activity.

Authors:  Meong Cheol Shin; Jian Zhang; Allan E David; Wolfgang E Trommer; Young Min Kwon; Kyoung Ah Min; Jin H Kim; Victor C Yang
Journal:  J Control Release       Date:  2013-08-23       Impact factor: 9.776

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.